At present, the main evidence-based medical evidence of belyumumab is still from lupus, so it is estimated that if we have the drug, it will still be mainly used in lupus patients.
Now the main evidence-based medical evidence for Bellevue monoantigen is still from lupus, so it is estimated that if we have the drug, it will be mainly used in lupus patients.
At present, the main evidence-based medical evidence of baileyumab is still from lupus, so it is estimated that if we have drugs, we will still mainly use them in lupus patients.<br>